Cxbladder excels in New Zealand
New Zealand clinicians and healthcare providers are excited about Pacific Edge Limited's cancer detection system Cxbladder for its ability to detect bladder cancer with a high degree of accuracy.
Two User Programmes in New Zealand on a combined study of 178 patients with macro-haematuria (blood in urine) has found that Cxbladderdetect outperforms cytology and saw 90% of all tumours. The full results are being prepared for publication.
The User Programme studies were conducted at two centres by Tony Beaven and Sue Osborne in conjunction with the Waitemata District Health Board (DHB); and Nick Buchan, Peter Davidson, Liz Mitchell and Barbara Gordon of Canterbury Urology Research Trust in conjunction with Canterbury DHB.
The study confirms the results of a larger, multi-centre Australasian study published last September in the peer reviewed Journal of Urology in the United States where Cxbladder outperformed the other commercially available tests benchmarked in the study. In that large study at a specificity of 85% Cxbladderdetect saw 100 % of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper urinary tract cancers. Cxbladderdetect also saw 97% of high grade tumours.
Pacific Edge's Commercial Manager, Brent Pownall, says the New Zealand user study demonstrates that Cxbladderdetect is a highly accurate and efficient detection test for urothelial carcinomas in the New Zealand healthcare context. "We look forward to having this product more widely used in New Zealand's healthcare programmes, thus benefiting DHBs, clinicians and patients alike."
"Cxbladderdetect gives clinicians and patients a high degree of assurance that the results are accurate which cytology cannot achieve to the same degree. In combination with cystoscopy, Cxbladderdetect will provide significant clinical upside, benefiting both patients and clinicians."
"Patients presenting with haematuria who are given the choice of providing a urine sample for Cxbladderdetect, or undergo an extensive work-up and experience the discomfort of cystocopy, are likely to choose Cxbladderdetect every time."
For our DHBs which are focused on providing the very best cost effective healthcare for New Zealanders, Cxbladderdetect provides a number of significant advantages:
- The Urine Sampling System can be sent directly to the patient at home, thereby minimising the need to queue to see a specialist and the inconvenience of another trip to the doctor or pathology lab collection centre
- Cxbladderdetect provides a cost effective way of evaluating patients presenting with haematuria before they get to the clinic and
- Cxbladderdetect does it in a non-invasive way.
Mid Central DHB based in Palmerston North is underway with their programme targeting Cxbladderdetect for yet another clinical value proposition that is expected to see a proportion of patients with haematuria, not having to come into the clinic for a full work-up.
Paul O'Sullivan, Pacific Edge's Clinical Science Manager, outlined that the User Programme studies for Waitemata and Canterbury are based on 178 patients presenting with haematuria undergoing investigations for possible urothelial carcinomas. All were tested using Cxbladderdetect as part of their clinical work-up. Results of the Cxbladderdetect test were compared with urine cytology and cystoscopic findings to determine the clinical utility of the Cxbladderdetect test.
"Cxbladderdetect proved its superiority over cytology by a wide margin in detecting 90% of the cases of urothelial carcinomas amongst the 178 patients. On one site Cxbladderdetect correctly detected 100% of the patients with urolthelial carcinoma. It also demonstrated its ability to correctly screen out patients who did not have urothelial carcinomas, which the study noted was particularly beneficial in patients presenting with haematuria."
The study results will be published by way of a presentation at the Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting in March 2014.